Understanding how glioma changes over a patient’s lifetime
Official title: Cataloging disease processes over the lifespan of glioma
Funded at Yale University · NIH-11424804 · Data updated 2026-11-12
A study to map how glioma tumors change from diagnosis through progression in many patients, to find patterns that could guide better treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 19, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $488,162 |
| NIH project number | 1R01CA315671-01 |
| Project ID | NIH-11424804 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with glioma who are undergoing standard treatments and have tumor tissue available for longitudinal analysis.
✕Less likely to help
Patients without access to serial tumor samples or those who are not enrolled in coordinated data collection may see no direct benefit.
What this research studies
This project follows glioma patients over time to track how tumors evolve after treatment. It relies on coordinated data from many hospitals to compare tumor changes at multiple time points. Researchers will analyze tumor samples and clinical data to build a comprehensive picture of heterogeneity and evolution in recurrent glioma. The effort is organized through an international consortium to achieve enough statistical power for meaningful insights. The goal is to identify new targets for therapies based on how tumors adapt over time.
Why it matters
Potential benefit: If successful, patients could benefit from more effective, tailored treatment strategies informed by how glioma evolves.
How similar studies have gone: Previous large-scale longitudinal cancer analyses have helped identify patterns of evolution and potential targets, though this specific glioma-focused effort is ongoing and expanding.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Verhaak, Roel Gw — Yale University
- Study coordinator: Verhaak, Roel Gw
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.